Navigation Links
Actavis Receives Approval of Generic Wellbutrin XL(R) 300mg in the U.S.
Date:8/18/2008

MORRISTOWN, N.J., Aug. 18 /PRNewswire/ -- Actavis Group, the international generic pharmaceuticals company, today announced that it has received approval from the U.S. Food & Drug Administration to market Bupropion Hydrochloride extended-release tablets (XL) 300mg. Distribution of the product will commence immediately.

Bupropion Hydrochloride extended-release tablets (XL), available in 300mg strength, are the generic equivalent of Wellbutrin XL(R) for the treatment of major depressive disorder. Annual US sales of brand and generic Wellbutrin XL(R) 300mg were US$581 million for the 12 months ending June 2008 according to IMS Health data.

Commenting on the new approval, Douglas Boothe, Chief Executive Officer of Actavis, Inc. said:

"Bupropion XL compliments our existing Buproprion SR offerings and expands the dosage options for our customers and patients. This approval also highlights Actavis Group's focus and expertise in bringing complex controlled-release technologies to the marketplace."

About Actavis

Actavis is one of the world's leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals. With headquarters in Iceland, Actavis has operations in 40 countries, with 11,000 employees. The United States is the company's single largest market. Actavis' U.S. operations are located in New Jersey, Maryland, North Carolina and Florida.

More information about Actavis in the United States can be found at http://www.actavis.us.

Information in this press release may contain forward-looking statements with respect to the financial condition, results of operations and businesses of Actavis. By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause ac
'/>"/>

SOURCE Actavis Group
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Harvard Business School Publishes a Case Study on Robert Wessman and Actavis
2. Actavis Extends Portfolio With Four New Products in the U.S.
3. Actavis Confirms its Patent Challenge of Kings Avinza(R)
4. Actavis Launches Amlodipine Tablets in the U.S.
5. Actavis Launches Carvedilol Tablets in the U.S.
6. New probe to detect skin cancer receives more funding for clinical trials
7. NUCRYST Receives Deficiency Notice from NASDAQ
8. Dr. Ajrawats Air-Pulse Autonomic Meditation Therapy, a Revolutionary, Scientific, Meditation Therapy, Receives Patent Trademark
9. PathNet Esoteric Laboratory Institute Main Laboratory Receives Accreditation From College of American Pathologists
10. Duska Therapeutics Receives Comments From FDA on Phase 3 ATPace(TM) Protocol Synopsis
11. Morris Animal Foundation Receives $1 Million Donation From Hills for Cat Health Research - Cat Lovers Have Reason to Celebrate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014 Coast Dental and Orthodontics ... its newest practice, located at 1010 Shaw Avenue in ... general dentistry services , and specialty dental care including ... providing affordable and convenient dental care, our Clovis dentists ... . Call Coast Dental at 559-777-6113 to schedule an ...
(Date:9/30/2014)... More than 23 per cent of Canadians report being stressed ... the risk of poor mental and physical health, not everyone ... others especially those most likely to sweat the small ... new research from Concordia University has found a way to ... for healthcare professionals working to stop stress before it gets ...
(Date:9/30/2014)... 30, 2014 OZ Naturals announced ... brand on Amazon.com. , “The majority of our products ... categories on Amazon.com,” said Craig Romero, CEO of OZ Naturals, ... Amazon.co.uk and Canada on Amazon.ca , Romero went on to ... earlier last month, are already taking over top positions and ...
(Date:9/30/2014)... cannot multiply and cardiac muscles contain few stem ... after a heart attack. Now Tel Aviv University ... in cardiac tissue engineering. , Dr. Tal Dvir ... Department of Biotechnology, Department of Materials Science and ... been developing sophisticated micro- and nanotechnological tools ...
(Date:9/30/2014)... 30th, 2014 A new report launched today ... Irish Longitudinal Study on Ageing) conducted by academics ... College Dublin, Ireland, has highlighted the serious, complex ... intellectual disability population. , The IDS-TILDA study is ... and the only one in the world with ...
Breaking Medicine News(10 mins):Health News:Coast Dental Clovis Celebrates Grand Opening 2Health News:Coast Dental Clovis Celebrates Grand Opening 3Health News:How to predict who will suffer the most from stress 2Health News:OZ Naturals Now the No. 1 Selling Beauty Brand on Amazon.com 2Health News:OZ Naturals Now the No. 1 Selling Beauty Brand on Amazon.com 3Health News:A heartbeat away? Hybrid 'patch' could replace transplants 2Health News:Longitudinal report shows challenging reality of ageing with an intellectual disability 2Health News:Longitudinal report shows challenging reality of ageing with an intellectual disability 3Health News:Longitudinal report shows challenging reality of ageing with an intellectual disability 4
... , AMSTERDAM and SAN DIEGO, July 15 ... that it has reached an agreement to acquire the assets of ... which involves the management of a patient,s body temperature. InnerCool, a ... ), will be acquired in an asset purchase transaction for US ...
... WESTFORD, Mass., July 15 Cynosure, Inc. ... manufacturer of a broad array of light-based aesthetic treatment systems, today ... on Tuesday, July 28, 2009 at 9:00 a.m. ET. , ... Executive Officer Michael Davin and Executive Vice President and Chief Financial ...
... , MORRISTOWN, N.J., July 15 ... specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, ... with the U.S. Food and Drug Administration seeking approval to ... the expiration of a patent owned by Supernus Pharmaceuticals, Inc. ...
... , , NASHVILLE, Tenn. and ... find that surveyed pharmacy directors of both national and single ... a medical benefit to a pharmacy benefit by 2014, citing ... will be most affected by this shift. According to the ...
... 15 While politicians spend countless hours bickering over how to ... aisle may be ignoring important research into this very subject, some ... Obama,s health care proposal contains flaws that will not only cost ... health care. , , ...
... , , SAN DIEGO, July ... announced today that its New Drug Application (NDA) for Acetavance(TM) (intravenous ... and fever in adults and children, has been accepted for filing ... Priority Review. Priority Review is granted to those products that address ...
Cached Medicine News:Health News:Philips Expands Emergency Healthcare Offering With Acquisition of InnerCool Therapies, a Leader in Body Temperature Management 2Health News:Philips Expands Emergency Healthcare Offering With Acquisition of InnerCool Therapies, a Leader in Body Temperature Management 3Health News:Cynosure To Announce Second-Quarter 2009 Financial Results On July 28 2Health News:Watson Confirms Filing of Abbreviated New Drug Application for Generic Sanctura XR(R) 2Health News:Intravenous Immune Biologics Will Suffer from the Pending Shift in Coverage from the Medical to the Pharmacy Benefit 2Health News:Intravenous Immune Biologics Will Suffer from the Pending Shift in Coverage from the Medical to the Pharmacy Benefit 3Health News:Will Government Health Care Make Us Sick? Health Expert Suggests 5 Shocking Flaws of Obamacare 2Health News:Cadence Pharmaceuticals Announces Priority Review and Acceptance of NDA Submission for Acetavance(TM) for Treatment of Acute Pain and Fever 2Health News:Cadence Pharmaceuticals Announces Priority Review and Acceptance of NDA Submission for Acetavance(TM) for Treatment of Acute Pain and Fever 3Health News:Cadence Pharmaceuticals Announces Priority Review and Acceptance of NDA Submission for Acetavance(TM) for Treatment of Acute Pain and Fever 4
(Date:9/30/2014)... 30, 2014  Come fall, many children, teenagers, and ... they want to be for Halloween. And, a number ... decorative contact lenses bought without a prescription. ... people purchase and wear contact lenses without a prescription. ... ® consumer survey, 17 percent of Americans have ...
(Date:9/30/2014)... Established and new medical technology service ... penetrate the growing Eastern European medical devices market. ... team and regional/local offices, reducing the costs incurred ... crucial advantage as medical technology service providers are ... New analysis from Frost & Sullivan, Medical Technologies ...
(Date:9/30/2014)... , September 30, 2014 ... diagnostic reagents is undergoing earthshaking changes. The country,s new ... administration of in-vitro diagnostic reagents are far from perfect ... the past 30 years. Chinese state council issued the ... Devices" on February 12, 2014, and it has come ...
Breaking Medicine Technology:The Spooky Truth: What You Need To Know About Contact Lens Hygiene 2The Spooky Truth: What You Need To Know About Contact Lens Hygiene 3Global Medical Manufacturers Turn to Distributors to Tap the Eastern European Market 2Global Medical Manufacturers Turn to Distributors to Tap the Eastern European Market 3Latest Chinese Guidebook for Application and Approval of Imported In-vitro Diagnostic Reagent Registration: From Regulations to Practices (2014 Edition) 2Latest Chinese Guidebook for Application and Approval of Imported In-vitro Diagnostic Reagent Registration: From Regulations to Practices (2014 Edition) 3Latest Chinese Guidebook for Application and Approval of Imported In-vitro Diagnostic Reagent Registration: From Regulations to Practices (2014 Edition) 4Latest Chinese Guidebook for Application and Approval of Imported In-vitro Diagnostic Reagent Registration: From Regulations to Practices (2014 Edition) 5
... , NEW YORK, Nov. 24 ... Ron Bentsur, the Company,s Chief Executive Officer, is scheduled to ... being held in New York City. , Mr. Bentsur,s presentation ... ET and will be accessible from the Investor Information page ...
... HealthWarehouse.com, Inc. (OTC Bulletin Board: HEWA) an online U.S. ... quarter ended September 30, 2009. The company reported quarterly revenue ... pharmacy transfers. Gross margins increased 13.0% year-over-year to 34.6% and ... a net loss of $186,299 for the three months ended ...
Cached Medicine Technology:Keryx Biopharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference 2HealthWarehouse.com, Inc. Announces Third Quarter Financial Results; Revenues, Margins, and Orders Shipped Increase Over Third Quarter 2008 2HealthWarehouse.com, Inc. Announces Third Quarter Financial Results; Revenues, Margins, and Orders Shipped Increase Over Third Quarter 2008 3
... are a convenient, reusable, patient-friendly and ... common orthopedic conditions/instabilities. These products are ... and lateral to medial influence of ... skin and soft tissue structures. Maximum ...
... The C.Ti.2 Hockey is a lightweight, ... meet the unique requirements of hockey,players. Tested ... a new, streamlined frame shape that is ... (VMO). Plus, the upper and lower lateral ...
... Drytex Adjustable Patella Donut is a ... nylon core and polyester Lycra Fabric ... trimable full-circumference donut provides for patellar ... neoprene based allergies or irritations. Click ...
The Deluxe Knee Immobilizer provides superb lightweight immobilization following injury or surgery. It is available in a wide array of sizes for excellent comfort and fit....
Medicine Products: